Document 3035
 DOCN  M94A3035
 TI    Prognostic value of CD4+ count and CD8+ T-cell activation in HIV
       seropositive patients.
 DT    9412
 AU    Declercq E; Lavreys L; Kestens L; Vanham G; Colebunders R; Gigase P;
       Institute of Hygiene and Epidemiology, Brussels, Belgium.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):169 (abstract no. PB0101). Unique
       Identifier : AIDSLINE ICA10/94369540
 AB    OBJECTIVE: To study the value of CD4+ T-lymphocytes and of the
       activation markers human leukocyte antigen (HLA)-DR and CD38 antigen on
       CD8+ cells in predicting the risk to develop clinical AIDS. METHODS: The
       selected population comes from a set of 753 HIV seropositive patients
       for whom CD4+ count and expression of CD38 and HLA-DR antigens on CD8+
       cells had been measured at the Institute of Tropical Medicine, Antwerp,
       between 1991 and 1993. A link based on a unique identification code was
       made between this set of data and the national HIV and AIDS registry in
       order to recognize which of these patients developed clinical AIDS in
       the following months. The final study population consists of 278 Belgian
       HIV seropositive patients who had not been diagnosed as AIDS patients at
       the time of the measurements. Techniques of survival analysis were used
       to study the probability of developing AIDS according to CD4+ count and
       expression of HLA-DR and CD38 antigens. RESULTS: The probability of
       developing AIDS was significantly lower (p < 0.0001) for the patients
       with CD4+ count equal to or higher than 400/mm3 than for those with less
       than 400 CD4+/mm3 (cumulative risk of developing AIDS after 36 months:
       24% vs. 37%). No difference was found in the risk of developing AIDS
       between the patients with high or low expression of HLA-DR antigen. For
       the patients with less than 400 CD4+/mm3, the risk of developing AIDS
       was significantly higher (p < 0.001) when there was a high expression of
       CD38 antigen (cumulative risk of developing AIDS after 36 months: 55%
       vs. 23%). The same trend, although not statistically significant, was
       observed for the patients with more than 400 CD4+/mm3 (cumulative risk
       of developing AIDS after 36 months: 35% vs. 18%). CONCLUSION:
       Measurement of CD38 expression on CD8+ cells together with CD4+ count
       could help estimating the individual prognosis than CD4+ count alone in
       HIV seropositive patients.
 DE    Acquired Immunodeficiency Syndrome/CLASSIFICATION/DIAGNOSIS/
       *IMMUNOLOGY  Antigens, CD8/*IMMUNOLOGY  Antigens, Differentiation/BLOOD
       Follow-Up Studies  Human  HIV
       Seropositivity/CLASSIFICATION/DIAGNOSIS/*IMMUNOLOGY  HLA-DR
       Antigens/BLOOD  *Leukocyte Count  Lymphocyte Transformation/*IMMUNOLOGY
       Risk Factors  T-Lymphocytes, Suppressor-Effector/*IMMUNOLOGY  T4
       Lymphocytes/*IMMUNOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).